In this study, M. pneumonia, L. pneumophila and C. pneumonia were only detected in about 4% of patients which is lower than in the prior Marston et al study- though this study relied on PCR which is more specific. Interestingly, Postma et al from April 2015 of NEJM showed non inferiority in 90 day mortality in beta lactam mono therapy vs beta lactam plus macrolide or fluoroquinolone alone in hospitalized, non-ICU patients. Given low levels of isolation of "atypical bacteria" in the current study, does this question need for empiric atypical coverage for all patients with community acquired pneumonia admitted to the hospital?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.